A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)
Public ClinicalTrials.gov record NCT06358950. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this research study is to assess the safety and efficacy of ALKS 2680 compared to placebo, including whether participants taking ALKS 2680 experience a greater decrease in sleepiness and a decrease in cataplexy ("sudden loss of muscle control"), compared to participants taking placebo alone.
Study identification
- NCT ID
- NCT06358950
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 92 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 24, 2024 (Actual)
- Primary completion
- Jun 19, 2025 (Actual)
- Completion
- Jul 31, 2025 (Actual)
- Last update posted
- Jun 10, 2026
2024 – 2025
United States locations
- U.S. sites
- 29
- U.S. states
- 13
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alkermes Investigational Site | Los Angeles | California | 90025 | — |
| Alkermes Investigational Site | Redwood City | California | 94063 | — |
| Alkermes Investigator Site | San Francisco | California | 94107 | — |
| Alkermes Investigational Site | Santa Ana | California | 92705 | — |
| Alkermes Investigational Site | Aurora | Colorado | 80045 | — |
| Alkermes Investigational Site | Colorado Springs | Colorado | 80918 | — |
| Alkermes Investigational Site | Brandon | Florida | 33511 | — |
| Alkermes Investigator Site | Brandon | Florida | 33511 | — |
| Alkermes Investigational Site | Miami | Florida | 33176 | — |
| Alkermes Investigator Site | Winter Park | Florida | 32789 | — |
| Alkermes Investigational Site | Atlanta | Georgia | 30328 | — |
| Alkermes Investigational Site | Macon | Georgia | 31210 | — |
| Alkermes Investigational Site | Stockbridge | Georgia | 30281 | — |
| Alkermes Investigator Site | Peoria | Illinois | 61637 | — |
| Alkermes Investigator Site | Lansing | Michigan | 48911 | — |
| Alkermes Investigator Site | Sterling Heights | Michigan | 48314 | — |
| Alkermes Investigator Site | Lincoln | Nebraska | 68506 | — |
| Alkermes Investigational Site | Middletown | New Jersey | 07748 | — |
| Alkermes Investigational Site | Denver | North Carolina | 28037 | — |
| Alkermes Investigational Site | Huntersville | North Carolina | 28708 | — |
| Alkermes Investigator Site | Canton | Ohio | 44718 | — |
| Alkermes Investigational Site | Cincinnati | Ohio | 45227 | — |
| Alkermes Investigational Site | Cincinnati | Ohio | 45245 | — |
| Alkermes Investigational Site | Dublin | Ohio | 43017 | — |
| Alkermes Investigational Site | Wyomissing | Pennsylvania | 19610 | — |
| Alkermes Investigational Site | Columbia | South Carolina | 29201 | — |
| Alkermes Investigational Site | Austin | Texas | 78731 | — |
| Alkermes Investigational Site | San Antonio | Texas | 78229 | — |
| Alkermes Investigational Site | The Woodlands | Texas | 77380 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06358950, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 10, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06358950 live on ClinicalTrials.gov.